Racura Oncology (ASX:RAC) partnered with Emory University to study RCDS1 in osimertinib-resistant, epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC), according to a Wednesday filing with the Australian bourse.
Osimertinib is the current standard of care treatment for NSCLC, the filing said.
Under the deal, the company gets access to Emory's osimertinib-resistant cell and mouse NSCLC models and expertise, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.